{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:21:39Z","timestamp":1781112099678,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ando.2025.101788","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T16:48:08Z","timestamp":1746809288000},"page":"101788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Livia","family":"Lamartina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Decaussin-Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Escande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Ciappuccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Al Ghuzlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101788_bib0185","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2025.101788_bib0190","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2025.101788_bib0195","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1089\/thy.2016.0100","article-title":"Systematic review of trends in the incidence rates of thyroid cancer","volume":"26","author":"Wiltshire","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0200","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/ijc.29251","article-title":"Thyroid cancer mortality and incidence: a global overview","volume":"136","author":"La Vecchia","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ando.2025.101788_bib0205","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1089\/thy.2023.0164","article-title":"Factors associated with survival in anaplastic thyroid carcinoma: a multicenter study from the ENDOCAN-TUTHYREF Network","volume":"33","author":"Jannin","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0210","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0215","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2025.101788_bib0220","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0225","series-title":"Endocrine and neuroendocrine tumours [Internet]","year":"2022"},{"key":"10.1016\/j.ando.2025.101788_bib0230","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1089\/thy.2023.0164","article-title":"Factors associated with survival in anaplastic thyroid carcinoma: a multicenter study from the ENDOCAN-TUTHYREF Network","volume":"33","author":"Jannin","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0235","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bulcan.2021.06.009","article-title":"Molecular genotyping in refractory thyroid cancers in 2021: when, how and why?. A review from the TUTHYREF network","volume":"108","author":"de la Fouchardi\u00e8re","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ando.2025.101788_bib0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/thy.2020.0312","article-title":"Immune profiling of advanced thyroid cancers using fluorescent multiplex immunohistochemistry","volume":"31","author":"Ahn","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0245","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","article-title":"Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy","volume":"60","author":"De Crevoisier","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ando.2025.101788_bib0250","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0255","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0260","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0265","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hed.21257","article-title":"Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy","volume":"32","author":"Bhatia","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.ando.2025.101788_bib0270","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/cncr.30493","article-title":"Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base","volume":"123","author":"Pezzi","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2025.101788_bib0275","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoto.2015.2332","article-title":"Aggressive palliation and survival in anaplastic thyroid carcinoma","volume":"141","author":"Nachalon","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ando.2025.101788_bib0280","doi-asserted-by":"crossref","first-page":"e230144","DOI":"10.1530\/ETJ-23-0144","article-title":"Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer","volume":"13","author":"Tan","year":"2024","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2025.101788_bib0285","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0290","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1200\/JCO.2021.39.15_suppl.6082","article-title":"Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: results of the AcS\u00e9 Pembrolizumab Study from Unicancer","volume":"39","author":"Leboulleux","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ando.2025.101788_bib0295","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0300","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0305","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.1016\/j.annonc.2021.08.710","article-title":"575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: a multicohort phase II trial (CABATEN trial\/GETNE-T1914)","volume":"32","author":"Grande","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0310","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1089\/thy.2022.0073","article-title":"An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma","volume":"32","author":"Hatashima","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0315","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0320","first-page":"13","article-title":"Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis","author":"Huang","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2025.101788_bib0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/ERC-20-0106","article-title":"Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview","volume":"28","author":"Sparano","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2025.101788_bib0330","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","article-title":"1646MO Phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0335","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ando.2025.101788_bib0340","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E\u2013mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0345","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0350","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2025.101788_bib0355","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2025.101788_bib0360","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1089\/thy.2019.0477","article-title":"Response to RET-Specific therapy in RET fusion-positive anaplastic thyroid carcinoma","volume":"30","author":"Dias-Santagata","year":"2020","journal-title":"Thyroid"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:50:33Z","timestamp":1751028633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0003426625001076"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101788","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101788"}}